Outcome prediction by the 2022 european leukemianet genetic-risk classification for adults with acute myeloid leukemia: an alliance study

HIGHLIGHTS

• who: Krzysztof Mru00f3zek from the Cytogenetic and molecular genetic analyses Cytogenetic analyses of pretreatment bone marrow (BM) and/or blood samples were performed by CALGB/Alliance-approved institutional laboratories and the results confirmed by central karyotype review [27]CN-AML was determined by analysis of u2265, metaphase cells from BM subjected to short-term (24-48-h) unstimulated cultures [27]. The mutational status of the ASXL1, BCOR, EZH2, NPM1, RUNX1, SF, SRSF2, STAG2, TP53, U , and , genes was determined centrally at The Ohio State University in patients` DNA extracted from viably frozen cells collected via companion protocol . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.